Determining Initial Gefitnib Concentration Using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenylterazolium Bromide (MTT) Assay
2:15
Continuous Stepwise Dose-escalation of Gefitnib Treatment of PC-9 Cells
3:31
Determine Initial Concentration of PHA665752 Using the MTT Assay
6:37
Results: Two-step Dose-escalation Procedure to Establish Dual Resistance to EGFT-TKI and MET-TKI
8:21
Conclusion
Transcription
The overall goal of this experiment is to discover novel mechanisms to overcome drug resistance. This method can help answer key questions in the cancer research field such as those about graft resistance. The main advantage of this technique is t
Connectez-vous ou commencez votre essai gratuit pour accéder à ce contenu.
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.